Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA | Zendy

Supriya D. Mahajan | Zendy; Ravikumar Aalinkeel | Zendy; Jessica L. Reynolds | Zendy; Bindukumar Nair | Zendy; Donald E. Sykes | Zendy; WingCheung Law | Zendy; Hong Ding | Zendy; Earl J. Bergey | Zendy; Paras N. Prasad | Zendy; Stanley A. Schwartz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA

Author(s) -

Supriya D. Mahajan,

Ravikumar Aalinkeel,

Jessica L. Reynolds,

Bindukumar Nair,

Donald E. Sykes,

WingCheung Law,

Hong Ding,

Earl J. Bergey,

Paras N. Prasad,

Stanley A. Schwartz

Publication year - 2011

Publication title -

pathology research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.398

H-Index - 21

eISSN - 2090-8091

pISSN - 2042-003X

DOI - 10.4061/2011/719139

Subject(s) - transactivation , gene silencing , human immunodeficiency virus (hiv) , small interfering rna , virology , rna interference , viral replication , long terminal repeat , microbiology and biotechnology , gene expression , biology , gene , rna , virus , genetics

HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research